Pyridoxal 5'-phosphate inhibition of lactate production in rat liver supernatant fluid

In vivo and in vitro inhibition of B16 melanoma growth by vitamin B6

The effect of vitamin B6 on the growth of B16 melanoma cells in vivo and in vitro was studied. B16 melanoma cells grown for three days in medium supplemented with 5.0 mM pyridoxine or 0.5 mM pyridoxal showed an 80% reduction in cell proliferation compared with control culture. Cells cultured for six hours in medium supplemented with 0.5 mM pyridoxal took up and incorporated 13 and 32% less [3H]thymidine, respectively, than did control cultures. A 17% reduction in [3H]glucose uptake was observed at this time point. When the incubation time was decreased to three hours, an inhibition of cellular uptake of [3H]thymidine (22%), [3H]uridine (14%), and [3H]glucose (15%) was observed; however, little or no inhibition in incorporation was detected. In in vivo studies, mice pretreated with pyridoxal for two weeks and then injected with B16 melanoma cells had a 62% reduction in tumor weight compared with controls at the end of a three-week period. If tumors were first established in mice and then treated with pyridoxal for six days, a 39% reduction in tumor growth was observed. There were no differences observed in body weights or liver weights in any of the animal groups. These results indicate that supraphysiological doses of vitamin B6 can inhibit the growth of B16 melanoma cells both in vitro and in vivo. The exact mechanism by which pyridoxal exerts its inhibitory effect was not ascertained, but experiments suggest that the vitamer may be acting on the plasma membrane to reduce precursor transport into the cell.

High-dose pyridoxal supplemented culture medium inhibits the growth of a human malignant melanoma cell line

The in vitro growth characteristics of a human malignant melanoma cell line cultured in 0.5 mM pyridoxal supplemented medium were studied. Experimentation revealed that the high-dose pyridoxal supplemented medium severely inhibited the growth of melanoma cells over a 72-hour growth period. Additional experimentation showed that cells cultured for 6 hours in the pyridoxal supplemented medium took up 25% less and incorporated 20% less [3H]uridine than control cultures. [3H]Glucose uptake was reduced by 23% at this time point. [3H]Thymidine uptake was inhibited by 12%, but no inhibition was detected in [3H]thymidine incorporation. When the vitamin B6 antagonist 4-deoxypyridoxine (which competes with pyridoxal for pyridoxal kinase) was added to the pyridoxal supplemented medium, the inhibition in [3H]uridine incorporation was reduced from 19% to 6%. However, 4-deoxypyridoxine did not reverse the inhibition of [3H]uridine uptake. These results indicate that pyridoxal and its metabolite, pyridoxal 5'-phosphate, may be involved in the growth regulation of a human malignant melanoma cell line.

Vitamin B6 kills hepatoma cells in culture

Data are presented which indicate that vitamin B6 (pyridoxine) can retard and eventually kill Fu5-5 rat hepatoma cells in culture. Additional studies indicate that the human kidney cell line 293-31, and a rat glial cell strain. C6, display growth characteristics similar to those of hepatoma cells when cultured in 5 mM pyridoxine-supplemented medium. However, the pyridoxine-supplemented culture medium had little effect on the growth of the human mammary cancer cell line MCF-7. The resistance of the MCF-7 cells to growth inhibition by vitamin B6 suggests that the vitamer pyridoxine must be metabolized by pyridoxal before it can act as a growth inhibitor. These findings suggest the potential use of vitamin B6 as an antineoplastic agent. Possible mechanisms by which vitamin B6 promotes this effect are presented.

The effect of pyridoxal phosphate on the activity of aldolase from Lemna minor L

Lemna aldolase has been purified by ion-exchange and affinity chromatography. The enzyme is inhibited by pyridoxal phosphate in a manner which suggests that pyridoxal phosphate forms a non-covalent complex with the enzymes which is in equilibrium with the Schiff base covalently modified enzyme. The kinetics of the reversal of inhibition have been used to test the proposition that the fall in aldolase activity observed during periods of nitrogen starvation is due to inhibition by pyridoxal phosphate. It is concluded that the in vivo loss of aldolase activity is not due to pyridoxal phosphate and that the in vitro inhibition of glycolytic enzymes by pyridoxal phosphate is due to the reaction with lysine residues at the active sites which are necessary to bind the strongly acidic sugar phosphates.